You are not logged in.

Have prohibition policies made the wrong decision? A critical review of studies investigating the effects of DMAA

Dunn, Matthew 2016, Have prohibition policies made the wrong decision? A critical review of studies investigating the effects of DMAA, International journal of drug policy, In Press, pp. 1-9, doi: 10.1016/j.drugpo.2016.10.005.

Attached Files
Name Description MIMEType Size Downloads

Title Have prohibition policies made the wrong decision? A critical review of studies investigating the effects of DMAA
Author(s) Dunn, Matthew
Journal name International journal of drug policy
Season In Press
Start page 1
End page 9
Total pages 9
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2016-11-14
ISSN 1873-4758
Keyword(s) 1,3-Dimethylamylamine
Summary In June 2012 DMAA (1,3-dimethylamylamine), an ephedrine-like vasoconstricting substance which had been included in many popular sports supplements, became a scheduled substance in Australia, following bans in several other countries. The underlying rationale for this ban was that DMAA use is unsafe. This paper aimed to critically review the available evidence on the acute and/or long-term harms of DMAA. Using five research databases (PubMed, Embase, ProQuest Health and Medical Complete, and Web of Science) and the key terms 'methylhexaneamine', 'DMAA', 'dimethylamylamine', '1,3-dimethylpentylamine' and '2-amino-4-methylhexane', 842 articles were identified once duplicates removed. Sixteen studies met the inclusion criteria and were included in the review. Of the included studies, eight were case studies, which reported on eight patients who presented to emergence departments. All were retrospective in their reporting. The patients displayed various outcomes; while the patients were presenting with serious problems, in most patients conditions subsided on cessation of supplement use. The remaining eight experimental studies were low powered, with a number of studies conducted by a single research group with industry ties, and broadly investigated the effects of DMAA on physiological outcomes. Mixed findings were apparent, although escalations of blood pressure were present on acute dosing, as well as decreases in measures of body weight and body fat. There is a shallow evidence base describing the adverse effects of DMAA and the dose above which such effects may occur. The scheduling of DMAA in many countries may now impede research efforts to determine whether there are safe doses at which DMAA can be consumed.
Language eng
DOI 10.1016/j.drugpo.2016.10.005
Field of Research 119999 Medical and Health Sciences not elsewhere classified
160508 Health Policy
Socio Economic Objective 920414 Substance Abuse
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Elsevier
Persistent URL

Document type: Journal Article
Collection: School of Health and Social Development
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 8 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Thu, 12 Jan 2017, 10:43:26 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact